Skip to main content

Advertisement

Table 3 Cost consequence analysis

From: Cost effectiveness of intermittent screening followed by treatment versus intermittent preventive treatment during pregnancy in West Africa: analysis and modelling of results from a non-inferiority trial

  IPTp-SP ISTp-AL
Costs per 1000 pregnant women Health provider excluding consequencesb (US$ 2012) 1631.84 (1100.11–2316.97) 5778.77 (4701.65–7039.15)a
Health provider including consequencesb (US$ 2012) 9006.54 (5610.30–13,680.56) 13,972.79 (10,199.65–18,983.86)a
Measurable outcomes contributing to DALYs per 1000 women [20] LBW 151 (137–167) 156 (141–172)
severe/moderate anaemia 17 (12–25) 23 (17–32)
clinical malaria (total episodes)c 74 (61–92) 115 (96–144)
Other measurable outcomes per 1000 women and side effects [20, 37] Placental malaria: active infection (acute and chronic) 245 (224–265) 242 (222–262)
Dizziness 46 (38–54) 25 (19–31)
Sleeplessness 13 (9–17) 7 (4–10)
Weakness 30 (24–37) 18 (13–23)
Nausea 22 (16–28) 13 (9–17)
Vomiting 45 (37–53) 26 (20–32)
Non measurable outcomes Intrinsic value of giving less drugs to pregnant women
Value to individual of knowing about positive test
Value of knowing about positive test for surveillance
Deprivation of treatment for false negatives
  1. DALY disability adjusted life years; IPTp-SP intermittent preventive treatment with sulfadoxine-pyrimethamine; ISTp-AL intermittent screening followed by treatment with artemether-lumefantrine; LBW low birth weight
  2. aAt 24.7 % of administration where RDT showed a positive result
  3. bCosts from consequences = ∑ short term costs LBW baby; costs mod/sev anaemia episode; costs MiP episode
  4. cClinical malaria defined as illness + positive slide at an unscheduled visit